Research transfer: Record funding for LMU spin-offs

They develop innovative therapeutics, software or quantum computers: companies that emerged as spin-offs from research groups at the Ludwig-Maximilians-Universität München (LMU) were particularly successful in attracting new capital last year. In total, they were able to raise around a quarter of a billion euros, enabling the young companies to further expand their research and development activities.

In addition to the entrepreneurial skill, successful research and development work and the viability of the start-up project, the record sum also and above all demonstrates the enormous innovative potential of basic research at LMU. All the companies are spin-offs from LMU or the LMU Medical Center, which have commercialized technologies developed here or in cooperation with other research institutions. They were initially advised by the LMU Spin-off Service.

LMU supports the transfer of research

LMU has developed a comprehensive range of services to support scientists in realizing the potential of their research results. The services offered by Transfer Management range from initial advice for those interested in setting up a business to support with funding and business plans and assistance in the search for suitable cooperation partners from industry.

Intellectual property management is also an important aspect of consulting, as it involves the exploitation of research results and the transfer of intellectual property.

The successful companies and their new financing in the medical sector:

• Tubulis GmbH develops technologies for the production of antibody drug conjugates (ADCs) for specific and gentle cancer treatment (funding raised in 2024: EUR 128 million)

• Smart Reporting GmbH works on software solutions that help radiologists and pathologists in particular to digitize their documentation and make it more efficient (EUR 23 million)

• deepc GmbH generates AI software systems for diagnostic imaging in radiology (EUR 12.6 million)

• Eisbach Bio GmbH develops drugs for precision oncology (EUR 8.9 million)

• Ethris GmbH, also from the biotech sector, is working on RNA therapeutics and vaccines (EUR 7.8 million)